我不明白，为什么不用ZFN来做？美国已经开始ZFN CCR5了。# Biology - 生物学
d*c
1 楼
https://www.sangamo.com/pipeline
Sangamo Therapeutics' approach uses ZFN-mediated genome editing in T-cells
to replicate a naturally occurring human mutation which renders individuals
largely resistant to infection with the most common strain of HIV. Sangamo
has an open label Phase 2 clinical study to evaluate safety and efficacy of
SB-728-T in T-cells.
Sangamo Therapeutics’ approach uses ZFN-mediated genome editing in HSCs to
replicate a naturally occurring human mutation which renders individuals
largely resistant to infection with the most common strain of HIV. An
investigator sponsored open label Phase 1/2 clinical study to evaluate
safety and efficacy of SB-728-HSPC in stem cells.
Sangamo Therapeutics' approach uses ZFN-mediated genome editing in T-cells
to replicate a naturally occurring human mutation which renders individuals
largely resistant to infection with the most common strain of HIV. Sangamo
has an open label Phase 2 clinical study to evaluate safety and efficacy of
SB-728-T in T-cells.
Sangamo Therapeutics’ approach uses ZFN-mediated genome editing in HSCs to
replicate a naturally occurring human mutation which renders individuals
largely resistant to infection with the most common strain of HIV. An
investigator sponsored open label Phase 1/2 clinical study to evaluate
safety and efficacy of SB-728-HSPC in stem cells.
